Molecular Pharmaceutics manuscript!


Our recently developed 5D3 mAb targeting prostate-specific membrane antigen (PSMA) has been successully functionalized by collaborators from Johns Hopkins (Artemov and Hapuarachchige groups) to elucidate efficacy of the ADC in a mouse model of prostate cancer! Congrat to all co-authors for this interesting story and also for a cover in Mol Pharm!